Management and Treatment of Centromere ANA Positive Patients

Clinical Significance and Diagnostic Approach

The presence of anticentromere antibodies (ACA) is primarily associated with limited cutaneous systemic sclerosis (lcSSc), occurring in 50-80% of these cases, and generally indicates a better prognosis compared to other scleroderma subtypes 2
When ACA is detected, a thorough evaluation for features of scleroderma spectrum disorders should be performed, including assessment for Raynaud's phenomenon, skin thickening, digital ulcers, and telangiectasias 2
Primary biliary cholangitis occurs in 8% of lcSSc cases, usually in those with anti-centromere antibodies; alkaline phosphatase is elevated, and generalized pruritus may occur 1, 2

Screen for pulmonary arterial hypertension (PAH) with echocardiography, pulmonary function testing, electrocardiography, NT-proBNP, and 6-minute walking distance, as PAH is a serious late complication in ACA-positive patients 1, 3
Evaluate for interstitial lung disease (ILD) through history, physical examination, chest radiography, pulmonary function testing, and high-resolution CT of the lungs when appropriate 1
Check liver function tests and consider screening for primary biliary cholangitis, especially with elevated alkaline phosphatase or pruritus 1
Monitor for scleroderma renal crisis with regular blood pressure checks and home blood pressure monitoring 1
Consider additional autoimmune testing including extractable nuclear antibodies (anti-Smith, anti-SSA/Ro, anti-SSB/La, anti-RNP, anti-Jo-1) to identify potential overlap syndromes 4

Treat gastrointestinal manifestations such as esophageal dysmotility with proton pump inhibitors and prokinetic agents 5
Monitor for and treat nutritional deficiencies if malabsorption is present due to gastrointestinal involvement 1
Screen for depression, which is elevated in patients with chronic diseases including systemic sclerosis 1
Consider bone density scanning for osteoporosis, which is increased in systemic sclerosis 1

Perform regular cardiovascular risk factor assessment and management, including hypertension, diabetes mellitus, hyperlipidemia, and smoking cessation 1